Unusually severe ABO hemolytic disease of Newborn

Goraya, Jatinder S.; Basu, Srikanta; Sodhi, Paveena; Mehta, Sunil

doi:10.1007/bf02723208

Cited by 14 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5,18 An unusually severe case of ABO HDN requiring two exchange transfusions within the first 24 hours has also been reported. 19 About half of the newborns (54.3%) who required phototherapy (16.6% of ABO-incompatible infants) had laboratory evidence of haemolysis, and three (12%) of them had a positive DCT. Direct antiglobin test positivity in as many as 26.1% of newborns with significant hyperbilirubinaemia has been reported.…”

Section: Discussionmentioning

confidence: 99%

Morbidity of ABO haemolytic disease in the newborn

Bhat

Chettiar

2012

Paediatrics and International Child Health

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Morbidity of ABO haemolytic disease in the newborn

Bhat

Chettiar

2012

Paediatrics and International Child Health

View full text Add to dashboard Cite

show abstract

“…Yet descriptions of unusually severe disease necessitating exchange transfusions and active intervention have been documented in the literature and also been reported by us. [1213]…”

Section: Spectrum Of Hemolytic Disease Of Newbornmentioning

confidence: 99%

Hemolytic disease of the fetus and newborn: Current trends and perspectives

Basu¹,

Kaur²,

Kaur³

2011

Asian J Transfus Sci

View full text Add to dashboard Cite

The spectrum of hemolytic disease of the newborn has changed over the last few decades. With the implementation of Rhesus D immunoprophylaxis, hemolytic disease due to ABO incompatibility and other alloantibodies has now emerged as major causes of this condition. Though in developing countries, anti D is still a common antibody in pregnant women, many Asian countries have identified alloantibodies other than anti D as a cause of moderate-severe hemolytic disease. The most concerned fact is that, some of these have been described in Rh D positive women. It appears that universal antenatal screening in all pregnant women needs to be initiated, since Rh D positive women are just as likely as D negative women to form alloantibodies. Many developed nations have national screening programs for pregnant women. This is necessary to ensure timely availability of antigen negative blood and reduce effects on the newborn. Although universal screening seems justified, the cost and infrastructure required would be immense. Developing countries and under resourced nations need to consider universal antenatal screening and frame guidelines accordingly.

show abstract

“…ABO blood group-caused hemolytic disease of the fetus and newborn (HDFN) is very frequent but only rarely severe [1][2][3][4][5][6][7][8][9]. The ABO blood group system is the only system in which natural IgM antibodies against the corresponding antigens are universally present from a young age, at approximately 4 months.…”

Section: Introductionmentioning

confidence: 99%

Next Generation Sequencing-Based Fetal ABO Blood Group Prediction by Analysis of Cell-Free DNA from Maternal Plasma

Rieneck

Hother

Clausen

et al. 2020

Transfus Med Hemother

View full text Add to dashboard Cite

Introduction: ABO blood group incompatibility between a pregnant woman and her fetus as a cause of morbidity or mortality of the fetus or newborn remains an important, albeit rare, risk. When a pregnant woman has a high level of anti-A or anti-B IgG antibodies, the child may be at risk for hemolytic disease of the fetus and newborn (HDFN). Performing a direct prenatal determination of the fetal ABO blood group can provide valuable clinical information. Objective: Here, we report a next generation sequencing (NGS)based assay for predicting the prenatal ABO blood group. Materials and Methods: A total of 26 plasma samples from 26 pregnant women were tested from gestational weeks 12 to 35. Of these samples, 20 were clinical samples and 6 were test samples. Extracted cell-free DNA was PCR-amplified using 2 primer sets followed by NGS. NGS data were analyzed by 2 different methods, FASTQ analysis and a grep search, to ensure robust results. The fetal ABO prediction was compared with the known serological infant ABO type, which was available for 19 samples. Results: There was concordance for 19 of 19 predictable samples where the phenotype information was available and when the analysis was done by the 2 methods. For immunized pregnant women (n = 20), the risk of HDFN was predicted for 12 fetuses, and no risk was predicted for 7 fetuses; one result of the clinical samples was indeterminable. Cloning and sequencing revealed a novel variant harboring the same single nucleotide variations as ABO*O.01.24 with an additional c.220C>T substitution. An additional indeterminable result was found among the 6 test samples and was caused by maternal heterozygosity. The 2 indeterminable samples demonstrated limitations to the assay due to hybrid ABO genes or maternal heterozygosity. Conclusions: We pioneered an NGS-based fetal ABO prediction assay based on a cell-free DNA analysis from maternal plasma and demonstrated its application in a small number of samples. Based on the calculations of variant frequencies and ABO*O.01/ABO*O.02 heterozygote frequency, we estimate that we can assign a reliable fetal ABO type in approximately 95% of the forthcoming clinical samples of type O pregnant women. Despite the vast genetic variations underlying the ABO blood groups, many variants are rare, and prenatal ABO prediction is possible and adds valuable early information for the prevention of ABO HDFN.

show abstract

Unusually severe ABO hemolytic disease of Newborn

Abstract: ABO-hemolytic disease of newborn (ABO-HDN) is a common cause of neonatal hyperbilirubinemia. Most of the cases are however mild. We describe a neonate with ABO-HDN with unusually severe course.

Cited by 14 publications

References 4 publications

Morbidity of ABO haemolytic disease in the newborn

Morbidity of ABO haemolytic disease in the newborn

Hemolytic disease of the fetus and newborn: Current trends and perspectives

Next Generation Sequencing-Based Fetal ABO Blood Group Prediction by Analysis of Cell-Free DNA from Maternal Plasma

Contact Info

Product

Resources

About